脑室内脑膜瘤（IVM）是颅内脑膜瘤的一种罕见亚型，占所有脑室内肿瘤的9.8%至14%。目前，对于哪些 IVM 患者应该接受保守治疗、手术或立体定向放射外科 (SRS) 尚无明确共识。本研究旨在分析结果，包括接受 SRS 进行 IVM 作为主要或辅助治疗的患者的生存率和复发率。截至 2023 年 6 月 5 日，在 Scopus、Web of Science、PubMed 和 Embase 中进行了系统检索。数据提取由两位独立作者进行。进行随机效应荟萃分析以确定接受 SRS 治疗的 IVM 病例的肿瘤控制比例。对随访时间内患者的无进展生存期（PFS）进行个体患者数据（IPD）荟萃分析。所有分析均使用 R 编程语言进行。在总共 132 条记录中，有 14 条包含在我们的研究中，其中只有 7 条有足够的数据进行荟萃分析。在接受 SRS 进行初次 IVM 的患者中，肿瘤控制比例为 0.92（95% CI，0.69-0.98）。原发病例和辅助病例的总体肿瘤控制率为 0.87（95% CI，0.34-0.99）。两项荟萃分析中异质性均不显着（分别为 P = 0.73 和 P = 0.92）。 71 例患者中有 16 例发生 SRS 后灶周水肿（0.16；95% CI，0.03-0.56），无显着异质性（P = 0.32）。 IPD 荟萃分析显示，2 年随访中的 PFS 为 94.70%。对数秩检验显示，与辅助 SRS 相比，初次 SRS 的 PFS 更好（P < 0.01）。根据这项研究，IVM 患者在接受 SRS 治疗时，无论是否接受 SRS 治疗，都可以实现较高的肿瘤控制率，且并发症风险较低。之前接受过治疗。尽管 SRS 可能是无症状 IVM 的一种有前景的一线治疗选择，但其对有症状患​​者的疗效及其与切除术的比较需要进一步研究。© 2024。作者。

Intraventricular meningioma (IVM) is a rare subtype of intracranial meningioma, accounting for 9.8 to 14% of all intraventricular tumors. Currently, there is no clear consensus on which patients with IVM should receive conservative treatment, surgery, or stereotactic radiosurgery (SRS). This research aims to analyze the outcomes, including survival and recurrence rates of patients who undergo SRS for IVM as a primary or adjuvant treatment.A systematic search was conducted in Scopus, Web of Science, PubMed, and Embase till June 5th 2023. Screening and data extraction were performed by two independent authors. Random-effect meta-analysis was performed to determine the tumor control proportion of IVM cases treated with SRS. Individual patient data (IPD) meta-analysis was performed for the progression-free survival (PFS) of the patients in the follow-up time. All analyses were performed using the R programming language.Out of the overall 132 records, 14 were included in our study, of which only 7 had enough data for the meta-analysis. The tumor control proportion was 0.92 (95% CI, 0.69-0.98) in patients who underwent SRS for primary IVM. The overall tumor control in both primary and adjuvant cases was 0.87 (95% CI, 0.34-0.99). the heterogeneity was not significant in both meta-analyses (P = 0.73 and P = 0.92, respectively). Post-SRS perifocal edema occurred in 16 out of 71 cases (0.16; 95% CI, 0.03-0.56), with no significant heterogeneity (P = 0.32). IPD meta-analysis showed a PFS of 94.70% in a 2-year follow-up. Log-rank test showed better PFS in primary SRS compared to adjuvant SRS (P < 0.01).According to this study, patients with IVM can achieve high rates of tumor control with a low risk of complications when treated with SRS, regardless of whether they have received prior treatment. Although SRS could be a promising first-line treatment option for asymptomatic IVM, its efficacy in symptomatic patients and its comparison with resection require further investigation.© 2024. The Author(s).